Infliximab in a Child With Relapsing Tuberculous Meningoencephalitis: A Case Report and Literature Review.

Pediatr Infect Dis JMay 4, 2026 (epub)
Case ReportInfectious DiseasesPediatricsNeurologyOpen access

Chiara Barone, Martina Capitani, Beatrice Fresch et al.

✦ AI-curated · Sources linked

Case in brief

A 5-year-old child with tuberculous meningoencephalitis experienced severe drug-induced hepatitis following standard antitubercular therapy, leading to the discontinuation of treatment. Despite switching to second-line drugs and high-dose corticosteroids, the child's condition worsened. The addition of infliximab resulted in significant clinical and radiologic improvement, suggesting its potential utility in refractory cases of central nervous system tuberculosis.

Diagnostic / clinical pearl

Infliximab may be considered in cases of refractory tuberculous meningoencephalitis, particularly when conventional therapies lead to severe adverse effects.

Source

PubMed · PMID 42081272Free full text on PubMed Central

Published in Pediatr Infect Dis J. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Infectious Diseases

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.